1. Home
  2. ESTA vs MESO Comparison

ESTA vs MESO Comparison

Compare ESTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

N/A

Current Price

$61.99

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$14.75

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESTA
MESO
Founded
2004
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
ESTA
MESO
Price
$61.99
$14.75
Analyst Decision
Strong Buy
Buy
Analyst Count
10
3
Target Price
★ $98.00
$37.00
AVG Volume (30 Days)
★ 467.3K
265.1K
Earning Date
10-29-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 42.67
N/A
EPS
N/A
★ N/A
Revenue
★ $61,208,000.00
N/A
Revenue This Year
$30.22
$51.63
Revenue Next Year
$24.46
$63.39
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 76.49
N/A
52 Week Low
$47.23
$11.89
52 Week High
$97.59
$21.50

Technical Indicators

Market Signals
Indicator
ESTA
MESO
Relative Strength Index (RSI) 43.98 55.05
Support Level $54.10 $13.77
Resistance Level $67.75 $16.06
Average True Range (ATR) 3.93 0.46
MACD 0.63 0.33
Stochastic Oscillator 41.24 71.76

Price Performance

Historical Comparison
ESTA
MESO

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: